Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial. Trial adds to rivalry with AbbVie. ... The news was a particular fillip for Galapagos, which saw its shares rise 6% on the announcement, with Gilead's shares also up.

Latest news

More from news
Approximately 138 fully matching, plus 325 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June

  • The race for an HIV ‘cure’ The race for an HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share. ... Gilead has also raised hopes after its candidate GS-9620, which aims to expel the virus from hidden reservoirs, made it through phase 1.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... US prices for Novartis’Kymriah and Gilead’s Yescarta are $475, 000 and $373, 000, respectively, for the

  • The good, the bad and the ugly The good, the bad and the ugly

    Gilead’s success with its curative Hep C portfolio had ultimately led to a diminishing population of target patients and played havoc with its revenues. ... Sanofi’s Lantus (-18.8%), Amgen’s Enbrel (-10.8%) and Gilead’s Harvoni (-48.5%) are among

More from intelligence
Approximately 2 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics